Iptacopan Hydrochloride

5 trials 5 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

1 Sponsors

12 Countries

Phase III

Phase II

Phase III/IV

Phase III: 3 Phase II: 1 Phase III/IV: 1

Oversight events:

2 corrective measures across 2 trials

View oversight register →

Indications tested

C3 glomerulopathy 2 Paroxysmal nocturnal haemoglobinuria 1 Lupus nephritis 1

Sponsors using this IMP

Novartis Pharma AG 5

All trials

5 total

Study to assess the pharmacokinetics, safety, and tolerability of iptacopan in pediatric PNH patients Recruiting

2024-515926-10-00 Phase III 5 countries Novartis Pharma AG
Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting

2023-509331-83-00 Phase III 7 countries Novartis Pharma AG
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting

2022-502160-20-00 Phase III 10 countries Novartis Pharma AG
Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting

2023-509332-26-00 Phase II 5 countries Novartis Pharma AG
Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting

2023-509343-27-00 Phase III/IV 7 countries Novartis Pharma AG

Showing 1–5 of 5 trials

← All drugs A–Z